Insights from Preclinical Choice Models on Treating Drug Addiction
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Substance-use disorders are a global public health problem that arises from behavioral misallocation between drug use and more adaptive behaviors maintained by nondrug alternatives (e.g., food or money). Preclinical drug self-administration procedures that incorporate a concurrently available nondrug reinforcer (e.g., food) provide translationally relevant and distinct dependent measures of behavioral allocation (i.e., to assess the relative reinforcing efficacy of the drug) and behavioral rate (i.e., to assess motor competence). In particular, preclinical drug versus food ‘choice’ procedures have produced increasingly concordant results with both human laboratory drug self-administration studies and double-blind placebo-controlled clinical trials. Accordingly, here we provide a heuristic framework of substance-use disorders based on a behavioral-centric perspective and recent insights from these preclinical choice procedures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurobiology of addiction: a neurocircuitry analysis
Koob, G. F., & Volkow, N. D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)00104-8 · Cited by 3,698 · cited 1×
“Second, emerging evidence has implicated the dynorphin/kappa opioid receptor (KOR) as one potential neurobiological modulator of drug reinforcement and, as a result, KORs may have therapeutic potential as a substance-use disorder pharmacotherapy target (reviewed in [67,68]).”
BackgroundSUBJECTIVE PROBABILITY AND DELAY
Rachlin, H., Raineri, A., & Cross, D. (1991) · Journal of the Experimental Analysis of Behavior · doi:10.1901/jeab.1991.55-233 · Cited by 1,341
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Sex Differences in Animal Models: Focus on Addiction
Becker, J. B., & Koob, G. F. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011163 · Cited by 725
Social dominance in monkeys: dopamine D2 receptors and cocaine self-administration
Morgan, D., Grant, K. A., Gage, H. D., Mach, R. H., Kaplan, J. R., Prioleau, O., Nader, S. H., Buchheimer, N., Ehrenkaufer, R. L., & Nader, M. A. (2002) · Nature Neuroscience · doi:10.1038/nn798 · Cited by 674 · cited 1×
“The results from these choice studies are generally consistent with sex differences in the potency of cocaine to function as a reinforcer under simple schedules of reinforcement [106,107].”
ResultBickel, W. K., Koffarnus, M. N., Moody, L., & Wilson, A. G. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.06.013 · Cited by 386 · cited 1×
“Emerging clinical and preclinical evidence has indicated that an individual's sensitivity to the temporal nature of reinforcer delivery may be a potential risk factor for substance use and substance-use disorders (reviewed in [6,46]).”
BackgroundControversies in translational research: drug self-administration.
Haney, M., & Spealman, R. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1079-x · Cited by 270 · cited 1×
“Second, as noted above, clinical treatment goals of substance-use disorders include not only decreasing drug-maintained behavior, but also increasing nondrug-maintained behavior [9,11,12,16].”
BackgroundDextroamphetamine for Cocaine-Dependence Treatment: A Double-Blind Randomized Clinical Trial
Grabowski, J., Rhoades, H., Schmitz, J., Stotts, A., Daruzska, L. A., Creson, D., & Moeller, F. G. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00010 · Cited by 243
Existing and future drugs for the treatment of the dark side of addiction
Koob, G. F., & Mason, B. J. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103143 · Cited by 121 · cited 1×
“Second, emerging evidence has implicated the dynorphin/kappa opioid receptor (KOR) as one potential neurobiological modulator of drug reinforcement and, as a result, KORs may have therapeutic potential as a substance-use disorder pharmacotherapy target (reviewed in [67,68]).”
BackgroundSchlosburg, J. E., Whitfield, T. W., Park, P. E., Crawford, E. F., George, O., Vendruscolo, L. F., & Koob, G. F. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1979-13.2013 · Cited by 119
Cited by
Volitional social interaction prevents drug addiction in rat models
Venniro, M., Zhang, M., Caprioli, D., Hoots, J. K., Golden, S. A., Heins, C., Morales, M., Epstein, D. H., & Shaham, Y. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0246-6 · Cited by 342
Improving translation of animal models of addiction and relapse by reverse translation
Venniro, M., Banks, M. L., Heilig, M., Epstein, D. H., & Shaham, Y. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0378-z · Cited by 212
Self-citationOperant Social Reward Decreases Incubation of Heroin Craving in Male and Female Rats
Venniro, M., Russell, T. I., Zhang, M., & Shaham, Y. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.05.018 · Cited by 127
Dopamine Circuit Mechanisms of Addiction-Like Behaviors
Poisson, C. L., Engel, L., & Saunders, B. T. (2021) · Frontiers in Neural Circuits · doi:10.3389/fncir.2021.752420 · Cited by 75
Science-Based Actions Can Help Address the Opioid Crisis
Epstein, D. H., Heilig, M., & Shaham, Y. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.06.002 · Cited by 42
Ahmed, S. H. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.07.005 · Cited by 39
Negus, S. S., & Banks, M. L. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.04.006 · Cited by 34
Self-citation
Metadata
- Authors
- Banks, M. L., & Negus, S. S.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 38
- Issue
- 2
- Pages
- 181-194
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2559087812
- Cited by
- 146
- References
- 16
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.